{"id":"https://openalex.org/W4361882452","doi":"https://doi.org/10.1158/1078-0432.22450140","title":"Supplementary Table 1 from Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations","display_name":"Supplementary Table 1 from Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361882452","doi":"https://doi.org/10.1158/1078-0432.22450140"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.22450140","doi":"https://doi.org/10.1158/1078-0432.22450140","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22450140","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/1078-0432.22450140","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5052382547","display_name":"Evita M. Lindholm","orcid":"https://orcid.org/0000-0001-9007-0827","observed_orcids":["https://orcid.org/0000-0001-9007-0827"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Evita M. Lindholm","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021789050","display_name":"Marit Krohn","orcid":"https://orcid.org/0009-0000-2077-3615","observed_orcids":["https://orcid.org/0009-0000-2077-3615"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marit Krohn","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017341589","display_name":"Sergio Iadevaia","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sergio Iadevaia","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108907870","display_name":"Alexandr Kristian","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alexandr Kristian","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005221518","display_name":"Gordon Brent Mills","orcid":"https://orcid.org/0000-0002-0144-9614","observed_orcids":["https://orcid.org/0000-0002-0144-9614"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gordon B. Mills","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053950619","display_name":"Gunhild Mari M\u00e6landsmo","orcid":"https://orcid.org/0000-0002-4797-1600","observed_orcids":["https://orcid.org/0000-0002-4797-1600"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gunhild M. M\u00e6landsmo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5050930640","display_name":"Olav Engebraaten","orcid":"https://orcid.org/0000-0002-0986-6957","observed_orcids":["https://orcid.org/0000-0002-0986-6957"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Olav Engebraaten","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.006899999920278788,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10631","display_name":"Cancer, Hypoxia, and Metabolism","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.8899999856948853},{"id":"https://openalex.org/keywords/breast-cancer-xenografts","display_name":"breast cancer xenografts","score":0.9259999990463257},{"id":"https://openalex.org/keywords/proteomics","display_name":"proteomics","score":0.7369999885559082},{"id":"https://openalex.org/keywords/protein-regulation","display_name":"protein regulation","score":0.9430000185966492},{"id":"https://openalex.org/keywords/drug-response","display_name":"drug response","score":0.6050000190734863},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7429999709129333},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.6679999828338623}],"concepts":[{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.8203005790710449},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.6216236352920532},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6078231930732727},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4864906668663025},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4539399743080139},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4488641023635864},{"id":"https://openalex.org/C45235069","wikidata":"https://www.wikidata.org/wiki/Q278425","display_name":"Table (database)","level":2,"score":0.4167683720588684},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.37105315923690796},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.3500255346298218},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3452141284942627},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3058519959449768},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.30117857456207275},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.208785742521286},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.1425943374633789},{"id":"https://openalex.org/C124101348","wikidata":"https://www.wikidata.org/wiki/Q172491","display_name":"Data mining","level":1,"score":0.07692983746528625}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/1078-0432.22450140","doi":"https://doi.org/10.1158/1078-0432.22450140","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22450140","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1078-0432.22450140.v1","doi":"https://doi.org/10.1158/1078-0432.22450140.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22450140.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_1_from_Proteomic_Characterization_of_Breast_Cancer_Xenografts_Identifies_Early_and_Late_Bevacizumab-Induced_Responses_and_Predicts_Effective_Drug_Combinations/22450140/1/files/39901200.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22450140","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Table_1_from_Proteomic_Characterization_of_Breast_Cancer_Xenografts_Identifies_Early_and_Late_Bevacizumab-Induced_Responses_and_Predicts_Effective_Drug_Combinations/22450140","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.22450140","doi":"https://doi.org/10.1158/1078-0432.22450140","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22450140","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4361882452.pdf","grobid_xml":"https://content.openalex.org/works/W4361882452.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2164442321","https://openalex.org/W4361950927","https://openalex.org/W4230798993","https://openalex.org/W2946754150","https://openalex.org/W2491116240","https://openalex.org/W2742128639","https://openalex.org/W2255135986","https://openalex.org/W2292285564","https://openalex.org/W3025772201","https://openalex.org/W2591127968"],"abstract_inverted_index":{"PDF":[0],"file":[1],"-":[2],"36K,":[3],"Supplementary":[4],"Table":[5],"1:":[6],"Protein":[7],"regulation":[8],"after":[9],"Bevacizumab":[10],"monotherapy.":[11]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-05T00:00:00"}